索拉非尼和舒尼替尼在转移性肾癌患者中的应用效果对比

Comparison of the effects ofsorafenib and sunitinib in patients with metastatic renal cell carcinoma

目的:比较索拉非尼和舒尼替尼在转移性肾癌患者中的应用效果。方法:选取2013年1月至2016年1月期间某院收治的132例转移性肾癌患者为研究对象,将患者依据随机数字表法分为A组和B组,各66例。A组患者给予索拉菲尼治疗,B组患者给予舒尼替尼治疗。比较2组患者的疾病控制、血液学毒性、不良反应和生存状况。结果:A组与B组患者的疾病控制率分别为87.88%和86.37%,差异无显著性(P>0.05)。B组患者的白细胞减少、中性粒细胞减少、血小板减少、贫血、肌酸激酶升高、转氨酶升高发生率均高于A组患者,差异具有显著性(P<0.05)。A组与B组患者高血压、皮疹、食欲不振、手足综合征、脱发的发生率比较差异无显著性(P>0.05)。B组患者腹泻和疲乏发生率均高于A组患者,差异具有显著性(P<0.05)。治疗后对患者随访2年,A组和B组患者疾病进展率分别为45.45%和40.90%,两组患者的疾病进展率、6个月、12个月和24个月生存率比较差异无显著性(P>0.05)。结论:索拉非尼和舒尼替尼治疗转移性肾癌患者疾病控制率和生存率差异无显著性,给予患者索拉菲尼治疗血液学毒性较小,给予患者舒尼替尼治疗腹泻发生率较高,但均无严重不良反应。

OBJECTIVE To compare the effects of sorafenib and sunitinib in patients with metastatic renal cell carcinoma.METHODS A total of 132 patients with metastatic renal cell carcinoma admitted to our hospital from January 2013 to January 2016 were enrolled.The patients were divided into group A and group B according to the random number table method,with 66 cases in each group.Patients in group A were treated with sorafenib and patients in group B were given sunitinib.Disease control,hematologic toxicity,adverse reactions and survival status were compared between the two groups.RESULTS The disease control rates of patients in group A and group B were 87.88%and 86.37%,respectively,and the difference was not statistically significant(P>0.05).The incidence of leukopenia,neutropenia,thrombocytopenia,anemia,creatine kinase,and transaminase elevation in group B were higher than those in group A,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of hypertension,rash,loss of appetite,hand-foot syndrome,and hair loss between group A and group B(P>0.05).The incidence of diarrhea and fatigue in group B was higher than that in group A,and the difference was statistically significant(P<0.05).After treatment,the patients were followed up for 2 years.The disease progression rates of group A and group B were 45.45%and 40.90%,respectively.There was no difference in the disease progression rate and survival rate at 6 months,12 months and 24 months between the two groups.(P>0.05).CONCLUSION There was no significant difference in disease control rate and survival rate between sorafenib and sunitinib in patients with metastatic renal cell carcinoma Patients who were given sorafenib have less hematologic toxicity,and patients administered with sunitinib have a higher incidence of diarrhea,but no serious adverse reactions occured.